Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards
Disease | Cell Type |
Therapeutic or Technology![]() |
Institution | Stage | Project Objective | Details |
---|---|---|---|---|---|---|
IPEX Syndrome, Immune Disease |
Vital Research Opportunity | Gene Therapy, cell free | Stanford |
![]() |
IND | |
Parkinson's Disease | Vital Research Opportunity | Gene Therapy, cell free | Brain Neurotherapy Bio |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Type 1 diabetes | Embryonic Stem Cell | Gene-modified, donor cell therapy | Lundquist Institute |
![]() |
Development Candidate, Proof of Concept | |
Liver Disease | iPS Cell | Gene-modified, donor cell therapy | CHLA |
![]() |
Development Candidate, Proof of Concept | |
COVID-19, Respiratory Disorders |
iPS Cell | Gene-modified, donor cell therapy | USC |
![]() |
Development Candidate, Proof of Concept | |
Blood Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | Angiocrine |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
COVID-19 |
Embryonic Stem Cell, iPS Cell |
Gene-modified, donor cell therapy | COH |
![]() |
Proof of Concept | |
Parkinson's Disease | Adult Stem Cell | Gene-modified, donor cell therapy | UCSF |
![]() |
IND | |
Amyotrophic Lateral Sclerosis | Adult Stem Cell | Gene-modified, donor cell therapy | Cedars-Sinai |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
Ovarian Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
![]() |
Pre-IND/IDE or Equivalent | |
COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
![]() |
Development Candidate, Proof of Concept | |
Ovarian Cancer | iPS Cell | Gene-modified, donor cell therapy | UCSD |
![]() |
Development Candidate, Proof of Concept | |
Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
B cell cancers, Leukemia |
Adult Stem Cell | Gene-modified, personalized cell therapy | Stanford |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Cancer | Cancer Stem Cell | Gene-modified, personalized cell therapy | UCSD |
![]() |
Pre-IND/IDE or Equivalent | |
Beta Thalassemia | Adult Stem Cell | Gene-modified, personalized cell therapy | Sangamo |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Pre-IND/IDE or Equivalent | |
Immune Disease, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | Orchard Therapeutics |
![]() |
Clinical Trial, Phase 2 | |
Cystinosis, Kidney Failure |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
HIV/AIDS | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Lung Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Brain Cancer, Breast Cancer |
Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
HIV-related Lymphoma, HIV/AIDS |
Adult Stem Cell | Gene-modified, personalized cell therapy | UC Davis |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Immune Disease, X-linked Chronic Granulomatous Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Leukemia, Acute Myeloid (AML) | Cancer Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Pre-IND/IDE or Equivalent | |
Canavan Disease | iPS Cell | Gene-modified, personalized cell therapy | COH |
![]() |
Pre-IND/IDE or Equivalent | |
Leukemia, Acute Myeloid (AML), Multiple Myeloma |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Pre-IND/IDE or Equivalent | |
Multiple Myeloma | Adult Stem Cell | Gene-modified, personalized cell therapy | Poseida Therapeutics |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Boston Children's Hospital |
![]() |
Clinical Trial, Phase 2 | |
Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
![]() |
IND | |
Epidermolysis Bullosa | iPS Cell | Gene-modified, personalized cell therapy | Stanford |
![]() |
Pre-IND/IDE or Equivalent | |
Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Development Candidate, Proof of Concept | |
Ovarian Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
![]() |
Development Candidate, Proof of Concept | |
Blood Disorders, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Proof of Concept | |
HIV/AIDS, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Bone or Cartilage Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Heart Disease, Danon Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
![]() |
Development Candidate, Proof of Concept | |
Hyper IgM Syndrome, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Pre-IND/IDE or Equivalent | |
Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
IND | |
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | St. Jude |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Sarcoma | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Blood Disorders | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
![]() |
Development Candidate, Proof of Concept | |
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Immune Disease, Leukocyte Adhesion Deficiency |
Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
![]() |
Clinical Trial, Phase 1 or Phase 1/2 | |
Hearing Loss | iPS Cell | Model system development | USC |
![]() |
Proof of Concept, Tool/Resources/Bottleneck | |
COVID-19, Respiratory Disorders |
Adult Stem Cell | Model system development | UCLA |
![]() |
Development Candidate, Proof of Concept, Tool/Resources/Bottleneck | |
COVID-19 | iPS Cell | Model system development | UC Berkeley |
![]() |
Proof of Concept |